

Submission No.: CS08-5347

Session : Concurrent Symposium 8 (Infection)

Date & Time, Place : November 18 (Fri), 15:40-17:10, Room 6F-2

Session Title : Vaccines: what, when, and how?

COVID-19 Vaccines and Transplant Patients: Lessons Learned

Dorry Segev

New York University, USA

COVID-19 Vaccines and Transplant Patients: Lessons Learned Dorry Segev, MD PhD
Professor of Surgery and Population Health Vice Chair, Department of Surgery Director,
Center for Surgical and Transplant Applied Research NYU Langone Health We have learned
many things from the COVID-19 pandemic, spanning from lessons in virology and biology,
lessons in patient care, and lessons in logistics and strategy during a time where it is
dangerous for us to interact with our patients. In terms of vaccines, our knowledge rapidly
evolved during the pandemic, and continues to evolve. Early on, we learned that vaccines
are safe but have limited immune response in the immunocompromised. We also figured out
that certain immunosuppressive agents reduce the immune response to the vaccines more
than others. We knew from biology that antibody response would be important, but we also
confirmed in large-scale trials that anti-spike antibodies correlate with neutralization and
protection, so these easy-to-measure surrogates can be used to identify the most vulnerable
of our patients. We discovered that some vaccine platforms work better than others; this
becomes more relevant with evolving variants, since Omicron neutralization requires a very
high vaccine response, much more than we had seen before. Finally, we are learning that
pre-exposure monoclonal antibodies are another approach, particularly for those unable to
mount an immune response to the vaccines. What lessons do we apply to future patient
care and research? We learned that existing registries and data collection help us learn and
track. We also learned that we need to advocate for our patients in clinical trials,
government policies, and clinical care. When things move quickly, we need to move quickly,
and moving quickly is easier in 2022 than ever before; however, traditional research designs
will not work, and traditional funding mechanisms will not work. We need to be more
creative. Also, when things move quickly, we need to rely on biology; if we think with a
Bayesian perspective, we can apply what little we can observe to the vast knowledge we
already have on the biology of our patients. Finally, we learned that media connects us to
our patients, and, perhaps even more importantly, media connects us to the world outside
transplantation.